Radiographic progression over 1 year stratified by clinical response at 3 months of MTX monotherapy
| ΔSHS from baseline | ΔSHS≤0 | ΔSHS> 0 | ΔSHS>3 | ΔSHS>5 | ||
|---|---|---|---|---|---|---|
| Mean (±SD) | Median | n (%) | n (%) | n (%) | n (%) | |
| Baseline MBDA score | ||||||
| Low (MBDA <30, N=5) | 0.8 (1.79) | 0 | 4 (80) | 1 (20) | 1 (20) | 0 |
| Moderate (MBDA 30–44, N=29) | 1.1 (2.07) | 0 | 19 (66) | 10 (34) | 4 (14) | 1 (3) |
| High (MBDA >44, N=201) | 3.4 (6.44) | 1 | 92 (46) | 109 (54) | 67 (33) | 42 (21) |
| Radiographic assessment at 1 year by response to MTX at 3 months* | ||||||
| Response to MTX (N=78) | 2.1 (4.36) | 0 | 40 (51) | 38 (49) | 15 (19) | 10 (13) |
| Non-response to MTX (N=157) | 3.6 (6.70) | 1 | 75 (48) | 82 (52) | 57 (36) | 33 (21) |
| Group A (N=77)† | 4.0 (6.90) | 1 | 36 (47) | 41 (53) | 28 (36) | 18 (23) |
| Group B (N=75)† | 3.2 (6.71) | 0 | 38 (51) | 37 (49) | 27 (36) | 15 (20) |
| Total cohort (N=235) | 3.1 (6.05) | 1 | 115 (49) | 120 (51) | 72 (31) | 43 (18) |
The proportions represent patients within a certain ΔSHS range out of respective baseline MBDA subgroups or treatments groups.
*Based on 235 patients with MBDA, DAS28-ESR, DAS28-CRP and CRP values at baseline plus radiographs at baseline and 1 year.
†Five of the 157 patients whose disease did not respond to treatment at 3 months did not undergo randomisation to group A (triple DMARD therapy) or group B (MTX+infliximab therapy).
CRP, C-reactive protein; DAS28-CRP, disease activity score based on C-reactive protein; DAS28-ESR, disease activity score based on erythrocyte sedimentation rate; MBDA, multi-biomarker disease activity; MTX, methotrexate, SHS, Sharp–van der Heijde score.